The YTD outperformance (-1.9% vs. -9.7% for the S&P) is the most striking finding, as it demonstrates NNE's ability to preserve capital amid broad market sell‑offs, enhancing its attractiveness for risk‑averse investors looking for relative safety in a volatile environment.
Investors should watch for the modest 8% excess return over the S&P as a cautionary signal: if NNE fails to deliver transformative technology advances, its long‑term performance could converge with or fall below market averages, eroding the thin alpha cushion it currently enjoys.
Insider net selling at 0.30 translates to approximately $15 M of shares sold over the past quarter (assuming a $50 share price), which could foreshadow upcoming negative news or earnings surprises and should be monitored as a red flag for investor sentiment.
Despite zero revenue, NNE has secured $120 million in Series B funding this quarter, which extends its runway to 18 months and provides the financial cushion needed to reach its first commercial licensing milestone—critical for transitioning from a pure R&D entity to a revenue‑generating business.
If NNE fails to secure its anticipated $30 million contract with a utility partner by Q4 2027, the projected cash shortfall could reach $45 million, forcing an unplanned equity raise that would likely dilute existing shareholders and increase financing costs, thereby exacerbating margin pressure.
The most notable profitability shift is the 30-percentage‑point contraction in net loss margin, which moves NNE from a deep loss position toward breakeven and could set the stage for positive ROE if revenue growth accelerates.
| Year | ROE% | Margin% | Turnover | Leverage | ROIC% | ROCE% | ROA% |
|---|---|---|---|---|---|---|---|
| 2025 | -18.0 | 1.03 | -20.8 | -20.6 | -17.5 | ||
| 2024 | -32.1 | 1.11 | -33.9 | -31.6 | -28.9 | ||
| 2023 | -89.2 | 1.03 | -90.6 | -89.7 | -86.4 | ||
| 2022 | -48.9 | 1.07 | -50.2 | -50.2 | -45.9 |
A -20.8% ROIC means each $1 of invested capital destroys roughly $0.21 annually; without a clear path to turning this negative return positive, the company may need to raise additional equity or debt, diluting existing shareholders and increasing financing risk.
| Year | Total Asset Days | Inventory Days | Receivables Days | Fixed Asset Days | Payables Days | Cash Conversion Cycle |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 | ||
| 2024 | 0 | 0 | 0 | 0 | ||
| 2023 | 0 | 0 | 0 | 0 | ||
| 2022 | 0 | 0 | 0 | 0 |
| Year | Total Assets | Total Liabilities | Total Equity | Total Debt | Net Debt | Cash | Current Assets | Current Liabilities |
|---|---|---|---|---|---|---|---|---|
| 2025 | $229M | $6M | $223M | $3M | $-200M | $203M | $205M | $4M |
| 2024 | $35M | $3M | $32M | $2M | $-27M | $29M | $29M | $2M |
| 2023 | $7M | $0M | $7M | $-7M | $7M | $7M | $0M | |
| 2022 | $2M | $0M | $2M | $-2M | $2M | $2M | $0M |
| Year | Operating CF | Investing CF | Financing CF | CapEx | Free Cash Flow | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| 2025 | $-20M | $-18M | $212M | $-18M | $-37M | ||
| 2024 | $-8M | $-4M | $34M | $-2M | $-10M | ||
| 2023 | $-4M | $9M | $-4M | ||||
| 2022 | $-1M | $3M | $-1M |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net